| Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for patients with neuroendocrine tumors: an Izmir Oncology Group Study T Salman, SN Kazaz, U Varol, U Oflazoglu, IT Unek, Y Kucukzeybek, ... Chemotherapy 61 (6), 281-286, 2016 | 64 | 2016 |
| Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan, E Akar, B Çakar, ... European urology focus 7 (5), 1061-1066, 2021 | 14 | 2021 |
| Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab D Tural, ÖF Ölmez, AT Sümbül, N Özhan, B Çakar, O Köstek, M Ekenel, ... International journal of clinical oncology 26, 1506-1513, 2021 | 12 | 2021 |
| Prevalence of depressive symptoms in elderly cancer patients receiving chemotherapy and influencing factors E Atag, F Mutlay, P Soysal, HS Semiz, SN Kazaz, M Keser, H Ellidokuz, ... Psychogeriatrics 18 (5), 365-370, 2018 | 10 | 2018 |
| The Rate of Neoadjuvant Chemotherapy Use in Muscle Invasive Bladder Cancer and The Approach of Urologists in Turkey O Üçer, AC Albaz, E Atag, A Karaoglu, T Muezzinoglu Urology Journal 13 (5), 2841-2844, 2016 | 10 | 2016 |
| Response to cabazitaxel beyond 20 cycles in a patient with penile metastasis of prostate cancer: a case report E Atag, HS Semiz, SN Kazaz, EB Tuna, O Ozdogan, O Bozkurt, O Demir, ... Urology Journal 14 (1), 2985-2988, 2017 | 8 | 2017 |
| The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and … EC Yildirim, E Atag, E Coban, OU Unal, A Celebi, M Keser, M Uzun, ... The Breast 70, 56-62, 2023 | 3 | 2023 |
| CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma HS Semiz, Ü Küçük, E Kısa, M Keskinkılıç, DE Süyün, ME Arayıcı, E Atağ, ... The Prostate 82 (16), 1564-1571, 2022 | 3 | 2022 |
| Does neoadjuvant chemotherapy provide any benefit for surgical de-escalation in luminal B, HER2 (-) breast cancers? A Aktas, M Gunay-Gurleyik, F Aker, Y Kaan-Akgok, E Atag Cirugía y cirujanos 91 (2), 186-194, 2023 | 2 | 2023 |
| Deficient mismatch repair and lymphocytic response to tumor as prognostic markers in stage II colon cancer patients M Sari, E Atag, T Demir, ET Simsek, E Coban, M Cikrikcioglu J Coll Physicians Surg Pak 32, 186-192, 2022 | 2 | 2022 |
| The role of FDG PET/CT to evaluation of axillary lymph nodes after neoadjuvant chemotherapy in breast cancer ET Simsek, E Coban, E Atag, S Gungor, M Sari, G Gurleyik JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN 31 (7), 792-797, 2021 | 2 | 2021 |
| What is your choice for androgen deprivation therapy in metastatic prostate carcinoma: surgical or medical? HS Semiz, E Kisa, EC Yildirim, E Atag, ME Arayici, T Muezzinoglu, ... Turkish Journal of Urology 48 (4), 287, 2022 | 1 | 2022 |
| Kas İnvaz Mesane Kanserinde Risk Adaptif Neoadjuvan Kemoterapi E Atağ, D Aziz Karaoğlu, Ö Küçük Bulletin of Urooncology 16, 57-62, 2017 | 1 | 2017 |
| Does immunohistochemical marker conversion affect the prognosis in breast cancer patients receiving neoadjuvant chemotherapy? M Uzun, E Atag, E Caliskan Yildirim, M Keser, HS Semiz, OU Unal Scientific Reports 14 (1), 14651, 2024 | | 2024 |
| Prognostic value of receptor status conversion after neoadjuvant chemotherapy in breast cancer patients M Uzun, E Atag, EC Yildirim, M Keser, HS Semiz, OU Unal | | 2024 |
| Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study S Sekmek, I Karahan, G Ucar, F Ceylan, D Bayram, I Seven, H Bölek, ... Clinical and Translational Oncology, 1-8, 2024 | | 2024 |
| 468P Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study EC Yildirim, E Atag, E Yuzugullu, OU Unal, A Celebi, M Keser, M Uzun, ... Annals of Oncology 34, S378, 2023 | | 2023 |
| 269P Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight EC Yildirim, HS Semiz, OU Unal, E Atag, A Karaoglu Annals of Oncology 34, S290, 2023 | | 2023 |
| Supportive Care or Specific Treatment? On Elderly Cancer Patients. S Gokcay, E Atag, ET Simsek Eurasian Journal of Medical Investigation 7 (2), 2023 | | 2023 |
| Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer B Akagündüz, DC Guven, M Ozer, IN Okten, E Atag, İT Unek, AM Tatli, ... Journal of Geriatric Oncology 14 (2), 101367, 2023 | | 2023 |
Hüseyin Salih SemizDokuz Eylül Üniversitesi在 deu.edu.tr 的电子邮件经过验证
